UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (ABT) following Abbott's agreement to acquire Exact Sciences for $105 per share. This acquisition, expected to close in Q2 2026, will expand Abbott's Diagnostics division and venture into cancer care with Exact Sciences' Cologuard test. UBS projects Abbott will outperform competitors in sales and EPS starting in 2026 due to its medical technology profile and double-digit growth.

雅培

<p>瑞士銀行重申了對雅培的買入評級和 158 美元的目標價，此次評級是在雅培收購 Exact Sciences 之後做出的，這標誌着今年醫療科技行業最大的收購。雅培被認為是一個值得投資的優質慢增長股票</p>

瑞銀在雅培實驗室（ABT）收購精確科學公司期間重申了買入評級